Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Algidol is a combination analgesic and antipyretic medication available in several countries, most notably Spain and some Latin American markets. Its formulation varies by country, but the most common version contains paracetamol (acetaminophen), codeine phosphate, and ascorbic acid (vitamin C). In some regions, formulations may also include ibuprofen or acetylsalicylic acid (aspirin). The primary mechanism of action involves pain relief through central inhibition of prostaglandin synthesis by paracetamol, opioid receptor agonism by codeine after hepatic conversion to morphine, and antioxidant effects from ascorbic acid. It is indicated for symptomatic treatment of moderate pain and febrile states[1][2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on algidol.